| DIRECT COMPETITOR COMPARISON | |
| AZN | GSK | MRK | NVS | Industry | | Market Cap: | 67.25B | 108.70B | 77.13B | 126.85B | 130.09M | | Employees: | 65,000 | 99,003 | 55,200 | 99,000 | 181 | | Qtrly Rev Growth (yoy): | 5.50% | 14.90% | 1.80% | 2.40% | 14.60% | | Revenue (ttm): | 32.05B | 45.11B | 23.37B | 42.31B | 31.21M | | Gross Margin (ttm): | 82.24% | 76.27% | 76.36% | 72.61% | 72.39% | | EBITDA (ttm): | 13.52B | 17.78B | 7.81B | 11.24B | -1.66M | | Oper Margins (ttm): | 37.85% | 34.30% | 26.63% | 21.50% | 2.37% | | Net Income (ttm): | 7.22B | 8.10B | 8.05B | 7.59B | N/A | | EPS (ttm): | 4.98 | 3.17 | 3.808 | 3.34 | N/A | | P/E (ttm): | 9.31 | 13.53 | 9.60 | 16.72 | 13.82 | | PEG (5 yr expected): | N/A | 3.06 | 2.12 | 2.83 | 2.12 | | P/S (ttm): | 2.05 | 2.38 | 3.27 | 2.97 | 3.30 |
|
| GSK = GlaxoSmithKline plc | | MRK = Merck & Co. Inc. | | NVS = Novartis AG | | Industry = Drug Manufacturers - Major | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.08 | 0.49% | 57.77B | 12.45 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 47.45 | 0.15% | 13.72B | 15.88 | | Genzyme Corp. | GENZ | 51.52 | 2.26% | 13.67B | 29.37 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.98 | 0.04% | 42.28B | 18.17 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.89 | 1.41% | 9.08B | 1038.57 | | Teva Pharmaceutical Industries Limited | TEVA | 53.16 | -0.21% | 46.83B | 48.64 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.81 | 2.05% | 4.01B | 19.49 | | Barr Pharmaceuticals, Inc. | Private - View Profile | | King Pharmaceuticals Inc. | KG | 12.08 | 0.00% | 3.00B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.29 | -0.05% | 5.59B | 112.21 | | Pfizer Inc. | PFE | 18.59 | 1.53% | 150.01B | 15.44 | | Johnson & Johnson | JNJ | 63.30 | 0.19% | 174.65B | 13.82 | | GlaxoSmithKline plc | GSK | 42.88 | 1.42% | 108.70B | 13.53 | | Sanofi-Aventis | SNY | 39.46 | 2.15% | 103.03B | N/A |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Novartis AG | NVS | 55.85 | 0.99% | 126.85B | 16.72 | | RHHBY.PK | 42.29 | 2.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.38 | 2.50% | 67.25B | 9.31 | | Abbott Laboratories | ABT | 54.41 | 0.31% | 84.16B | 14.74 | | Bristol-Myers Squibb Co. | BMY | 25.65 | 1.95% | 50.81B | 13.27 |
|
| NEWS ON DIRECT COMPETITORS | |
| | MRK | | INSIDE WASHINGTON: Stream of WH health care visits Thu 4:11pm -
AP | | | MRK | | Zetia's Miraculous Popularity Thu 3:22pm -
at Forbes.com | | | GSK | | Theravance, Inc.: Wait to Buy on Dip Thu 6:19am -
at Seeking Alpha | | | NVS | | Novartis Partners with U.S. Government for Faster Flu Vaccine Manufacturing Thu 3:34am -
at Seeking Alpha | | | MRK | | Merck Triumphant in Defense of Osteoporosis Drug.. for Now Thu 3:27am -
at Seeking Alpha | | | MRK | | AP IMPACT: A stream of WH health care visits Wed, Nov 25 -
AP | | | MRK | | Who's Visiting the White House? Wed, Nov 25 -
at Forbes.com | | | NVS | | [$$] Charting the Market Wednesday Wed, Nov 25 -
at Barrons.com | | | MRK | | Sitting Atop An Earnings Powder Keg Wed, Nov 25 -
at Forbes.com | | | NVS | | TradingMarkets 7 Stocks You Need to Know for Friday Wed, Nov 25 -
TradingMarkets.com | | | NVS | | Incyte Shares Up on Novartis Licensing Deal Wed, Nov 25 -
at Fox Business | | | NVS | | Dream Stocks for Biotech Investors Wed, Nov 25 -
at Motley Fool | | | NVS | | Prospecting for Stocks: Novartis Wed, Nov 25 -
at Motley Fool | | | GSK | | A Schizophrenic Move by Merck? Wed, Nov 25 -
at Motley Fool | | | GSK | | Human Genome Begins Trial Wed, Nov 25 -
Zacks.com | | | GSK | | [video] Topping the Tape Tue, Nov 24 -
at CNBC | | | GSK | | How Big Pharma Profits from Swine Flu Tue, Nov 24 -
at BusinessWeek | | | GSK | | Batch of swine flu vaccines studied in Canada Tue, Nov 24 -
AP | | | GSK | | GlaxoSmithKline pulls swine flu vaccines in Canada Tue, Nov 24 -
AP | | | All Headlines for these symbols... |
|
|
|